Estuary Biotherapeutics
Estuary Biotherapeutics develops locally delivered gene therapies for patients with inherited polycystic kidney disease.
$93MSeries A
ParticipantDT
Deep Track Capital
Activity from announced rounds
All recorded activity
Deep Track Capital is a life-sciences investor identified by Draig Therapeutics and Superluminal Medicines.
Recorded funding activity
Superluminal combines structural biology, protein dynamics, machine learning and experiments to discover small-molecule medicines. Draig develops neuropsychiatric treatments, while Triveni works on antibodies for immunological and inflammatory disorders. These company relationships give context to the recorded financings.
- Rounds participated in
- 6
- Confirmed lead rounds
- 1 3 roles undisclosed
- New companies
- 6 First participation on record · 0 follow-on
- Funding in participating rounds
- $491M 6 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
6 in all activitySuperluminal Medicines
Superluminal Medicines combines structural biology, protein dynamics, machine learning and experimental testing to discover small-molecule drugs for difficult G protein-coupled receptor targets. Its pipeline focuses on endocrine and cardiometabolic diseases, including rare genetic and hypothalamic obesity.
$60MSeries B
ParticipantDraig Therapeutics
Draig Therapeutics develops neuropsychiatric medicines.
$65MSeries B
Role not disclosedTriveni Bio
Develops novel antibody treatments for immunological and inflammatory disorders
$65MSeries C
Role not disclosedTerremoto Biosciences
Develops highly targeted, small molecule medicines for cancer and rare diseases
$108MSeries C
Role not disclosedAmbrosia Biosciences
Drug-discovery company developing oral small-molecule treatments for obesity and metabolic disorders.
$100MSeries B
Lead